From May 4 to 8, 2025 (GMT -6), Salt Lake City, Utah, welcomed over 10,000 leading scientists and clinicians from more than 70 countries for the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO)—one of the most prestigious global events in vision science and ophthalmology.
As a biotechnology and biomaterial company, Bloomage actively participated in this international gathering, presenting our innovative solutions and biomaterial expertise for ophthalmology.
Innovative Products & Solutions for Ocular Ophthalmology
At ARVO, Bloomage showcased several core ingredients for applications including dry eye relief, allergy relief, post-surgery&wound healing, and contact lens care.
Our flagship product, Hyatrue® pharmaceutical-grade sodium hyaluronate, is available in three grades (eye drop, injection, and sterile powder), with molecular weights ranging from 3 kDa to 3.5 MDa. This product meets diverse needs across ophthalmic formulations such as eye drops, viscoelastic agents, contact lens care solutions, and emerging applications like cell therapy.
Bloomecto™ Ectoine is an osmotic pressure protectant that helps preserve the activity of lysozyme—an important defensive protein in the tear film, stabilizes the tear film, and protects and repairs the eye from external damage. Derived through fermentation, high-purity pharmaceutical-grade Bloomecto™ Ectoine is produced without the use of organic solvents and holds comprehensive regulatory qualifications.
Ergothioneine is a naturally occurring antioxidant that plays a vital protective role in human cells and is recognized as an important bioactive compound. It is present in the lens and tear fluid of the eye; however, the human body cannot synthesize ergothioneine and must obtain it through dietary intake. With its potent antioxidant activity, ergothioneine is highly effective at scavenging reactive oxygen radicals, thereby protecting cellular DNA and mitigating photoaging. Studies have demonstrated its potential in safeguarding ocular tissues from oxidative damage. Our company produces ultra-pure ergothioneine through a fermentation-based process, achieving 99% purity, which shows strong promise for ophthalmic applications.
Latest Research Developments Presented
Dr. Xin Sun from the Bloomage R&D team presented a research abstract titled:"Pre-clinical Evaluation of Ectoine-Based Binary Combinations in Alleviating Dry Eye."
Ectoine has been widely used in the relief and treatment of dry eye and ocular allergies due to its excellent properties in protein and cell membrane protection, tear film stabilization, and anti-inflammatory activity. This study focused on the synergistic effects of low-concentration ectoine in combination with other components for the treatment of dry eye—offering new formulation strategies for dry eye therapy.
Bloomage’s presence at ARVO 2025 highlighted our continued commitment to innovation in ophthalmology and helped strengthen connections with global partners. Looking ahead, we remain dedicated to advancing the field through cutting-edge research and high-quality raw material solutions.
